News
![]() |
Portfolio project going IPO30 September 2021 Acticor Biotech, Primer Capital's portfolio project, announces its projected IPO on the Euronext Growth market in Paris
|
![]() |
Acticor Biotech, Primer Capital's portfolio project, announces its projected IPO on the Euronext Growth market in Paris
|
![]() |
Primer Capital at the Sirius Summit10 May 2021 On April 26-30, 2021, Anton Lavrentiev, CEO of Primer Capital took part in the Big Challenges Summit at Sirius as a speaker in the mini-symposium "Technology Entrepreneurship: The Path to the New Economy".
|
![]() |
Primer Capital at the Sirius Summit On April 26-30, 2021, Anton Lavrentiev, CEO of Primer Capital took part in the Big Challenges Summit at Sirius as a speaker in the mini-symposium "Technology Entrepreneurship: The Path to the New Economy".
|
![]() |
Primer Capital CEO spoke at the Russian Venture Forum in Kazan9 April 2021 Anton Lavrentiev at the "Venture Capital Market 2020: Trends and Challenges" panel at the central event of the Russian venture capital industry in Kazan.
|
![]() |
Primer Capital CEO spoke at the Russian Venture Forum in Kazan Anton Lavrentiev at the "Venture Capital Market 2020: Trends and Challenges" panel at the central event of the Russian venture capital industry in Kazan.
|
![]() |
ATLAS has become the first in Russia to register a test which detects 6 oncogenes simultaneously18 March 2021 Primer Capital portfolio project, Atlas has become the first company in Russia to receive marketing authorization for its kit which can simultaneously detect 6 mutations in the BRAF, EGFR, KRAS, NRAS, KIT, PDGFRA genes in tumor samples.
|
![]() |
ATLAS has become the first in Russia to register a test which detects 6 oncogenes simultaneously Primer Capital portfolio project, Atlas has become the first company in Russia to receive marketing authorization for its kit which can simultaneously detect 6 mutations in the BRAF, EGFR, KRAS, NRAS, KIT, PDGFRA genes in tumor samples.
|
![]() |
Primer Capital's CEO Spoke at the Private Equity and M&A Conference15 February 2021 The CEO of Primer Capital, Anton Lavrentiev, spoke at the Private Equity and M&A conference on February 11-12, 2021.
|
![]() |
Primer Capital's CEO Spoke at the Private Equity and M&A Conference The CEO of Primer Capital, Anton Lavrentiev, spoke at the Private Equity and M&A conference on February 11-12, 2021.
|
![]() |
Primer Capital's portfolio project closed an investment round23 December 2020 Botkin.AI, a platform for analyzing and processing CT scans using AI using raised RUB 160 million in a round of funding.
|
![]() |
Primer Capital's portfolio project closed an investment round Botkin.AI, a platform for analyzing and processing CT scans using AI using raised RUB 160 million in a round of funding.
|
![]() |
Primer Capital is the winner of the National Venture Investor Award 202028 October 2020 The fund won the Best Syndicated Deal nomination for its investment in Botkin.AI project
|
![]() |
Primer Capital is the winner of the National Venture Investor Award 2020 The fund won the Best Syndicated Deal nomination for its investment in Botkin.AI project
|
![]() |
Acticor Biotech Announces the Success of its Phase I study with Glenzocimab In Patients with Acute Ischemic Stroke1 October 2020 Primer Capital's portofolio project, a France-based clinical stage biotechnology company today announced the completion of its Dose Escalation Phase of Glenzocimab Study.
|
![]() |
Primer Capital's portofolio project, a France-based clinical stage biotechnology company today announced the completion of its Dose Escalation Phase of Glenzocimab Study.
|
![]() |
Primer Capital’s Portfolio Project has filed for an IPO4 September 2020 US-based Athira Pharma, a project financed by Primer Capital, is planning to go public.
|
![]() |
Primer Capital’s Portfolio Project has filed for an IPO US-based Athira Pharma, a project financed by Primer Capital, is planning to go public.
|
![]() |
Portfolio project becomes a winner of AstraZeneca Skolkovo Accelerator3 July 2020 The GemoPharm company was announced the winner of the scientific track within the acceleration program by AstraZeneca Skolkovo StartUp Challenge 2020.
|
![]() |
Portfolio project becomes a winner of AstraZeneca Skolkovo Accelerator The GemoPharm company was announced the winner of the scientific track within the acceleration program by AstraZeneca Skolkovo StartUp Challenge 2020.
|
Записи 1 - 10 of 71
First | Prev. | 1 2 3 4 5 | Next | Last